Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …

The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …

In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

Background Cancer is the most prevalent cause of death globally, and radiotherapy is
considered the standard of care for most solid tumors, including lung, breast, esophageal …

Metastasis is the primary cause of cancer mortality, and cancer frequently metastasizes to
the liver. It is not clear whether liver immune tolerance mechanisms contribute to cancer …

Since the first connection between Fenton chemistry and biomedicine, numerous studies
have been presented in this field. Comprehensive presentation of the guidance from Fenton …

Transforming growth factor-β (TGFβ) signalling controls multiple cell fate decisions during
development and tissue homeostasis; hence, dysregulation of this pathway can drive …